argenx SE
XBRU:ARGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
argenx SE
XBRU:ARGX
|
NL |
|
C
|
Compagnie De l'odet SE
OTC:FCODF
|
FR |
|
C
|
Corning Inc
XMUN:GLW
|
US |
|
Holcim AG
SIX:HOLN
|
CH |
Intrinsic Value
Is ARGX undervalued or overvalued?
See the intrinsic value estimate for argenx SE and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
ARGX looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with ARGX’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What argenx Does
argenx is a biotechnology company that develops antibody-based medicines for serious autoimmune diseases, where the body attacks its own tissues. Its best-known product is VYVGART, a prescription therapy used by specialist doctors and hospitals to treat certain immune disorders. The company also has a pipeline of follow-on drug candidates built around the same antibody engineering platform.
- Headquarters
- Netherlands NL
- Employees
- 1 863
- IPO date
- Jul 10, 2014
argenx has a narrow economic moat
Patents covering Vyvgart’s active medicine and its uses prevent rivals from freely copying argenx’s main treatment. This protects its profits without shutting out competing medicines such as UCB’s Rystiggo and Johnson & Johnson’s Imaavy.
Read the full moat analysisLatest Earnings Call
- EPS
- €7.32
- Expected
- €6.52
- Surprise
- +12.3%
- Stock, day of the call
- +5.1%
Earnings Waterfall
argenx SE
The intrinsic value for argenx SE (ARGX) under the Base Case is hidden EUR.
Compared with the current market price of 786.6 EUR, the stock appears hidden.